Trial comparing treatments for Shock, Cardiogenic
Official title CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
ClinicalTrials.gov ID: NCT05267886
What this study is testing
What is Dobutamine?
An investigational drug being studied for treating cardiogenic shock in critically ill patients. It is designed to increase the pumping function of the heart by stimulating beta-adrenergic receptors.
Also referred to as Dobutrex, Inotrex.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see whether giving inotropes (Milrinone or Dobutamine) improves outcomes for critically ill patients with cardiogenic shock compared to a placebo.
- Who it's for
- Patients in the cardiac intensive care unit who need heart‑boosting medication as decided by their doctor.
- What's involved
- Participants receive either an inotrope or a placebo for 12 hours while doctors monitor them closely. After 12 hours the treatment is open‑label and doctors decide whether to keep using the drug.
- Time commitment
- The study lasts 12 hours of blinded treatment, followed by open‑label care; visits are limited to routine ICU monitoring.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adult patients ≥ 18 years of age admitted to an intensive care unit
- SCAI class C or D cardiogenic shock
You likely can't join if
- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients who are currently pregnant or breast-feeding
- Patients presenting with an out-of-hospital cardiac arrest (OHCA)
- Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization
- Severe obstructive valvular lesions, including aortic stenosis and/or mitral stenosis
- Dynamic left ventricular outflow tract obstruction
The study team makes the final eligibility decision.
Where it is enrolling
- Hamilton, Ontario, Canada
- Ottawa, Ontario, Canada
Compensation & support
A stipend or payment for your time may be offered.
No amount is published here because ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team, so confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Hamilton, Ontario, Canada; Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.